EMV Capital (LSE:EMVC), the venture Investment group, has changed its key market advisers. On 9 November 2026 the company announced that Grant Thornton UK Advisory & Tax LLP had been appointed as its nominated adviser and Shore Capital Stockbrokers Limited as its broker, both with immediate effect. The move follows interim results in September that showed a sharp rise in net asset value per share, largely driven by an accounting change.
Company Overview
EMV Capital invests in and supports early-stage technology and life sciences businesses, and manages funds on behalf of other investors. Its core operations earn Revenue from value creation services and corporate finance fees, alongside the potential for gains on its own holdings.
Portfolio companies named in recent announcements include Glycotest, ProAxsis and AMR Bio, as well as a newly added Business that acquired a recycling plant in September 2026. This spread of holdings across healthcare and deep technology reflects the focus of LSE:EMVC on companies at an early stage of development.
Alongside its own investments, the group manages funds for other investors, and the level of Assets under management is therefore an important indicator of the scale of the platform. Revenue from value creation services and corporate finance fees provides income that is not dependent on the timing of any individual exit.
Latest Developments
The adviser change is the most recent formal announcement. A nominated adviser is required for every AIM company, and changes of this kind can accompany a shift in strategy or simply reflect a review of service providers. The company also Issued Shares in early November, in an announcement covering a dealing by a person discharging managerial responsibilities and an update to total voting rights.
For investors, the identity of the nominated adviser and broker is relevant because these firms support the company's dealings with the market and its compliance with AIM rules. The appointments took effect immediately, so the new team is already in place to assist with any forthcoming announcements, fundraising or transactions.
On 13 October 2026, EMV Capital reported that portfolio company Glycotest had taken an exclusive worldwide licence to intellectual property from the Medical University of South Carolina. Glycotest is developing a blood test to stage liver fibrosis, and the licensed biomarker is intended to strengthen its existing approach by combining markers into panels. The licence includes royalties and other financial terms for the university, though no figures were disclosed.
Combining several biomarkers into a panel is a recognised way of improving the information a diagnostic test can provide, as a single marker may not capture the full picture of a condition. The licence therefore adds to the intellectual property base that Glycotest can draw on as it develops its test.
Financial Picture
Interim results for the six months to 30 June 2026, released on 24 September, reported assets under management of £117.5 million, up from £112.5 million at the end of 2025. Net assets were £33.4 million and net asset value per share rose 145% to £1.20. That increase was largely due to the deconsolidation of Glycotest and ProAxsis, which generated a non-cash gain of £25.1 million.
As a result the group reported a profit of £17.8 million, while the underlying result excluding that gain was a net loss of £2.1 million. Revenue from EMV Capital's core operations rose 9% to £1.5 million. Cash at the period end was £0.7 million. No Dividend was reported.
Deconsolidation means that a holding is no longer combined line by line into the group accounts, and its value is instead reflected as an investment. That accounting treatment explains why the net asset value per share moved so sharply without a corresponding movement in cash.
The £25.1 million gain is a measure of how the holdings were valued when they ceased to be consolidated, and it does not represent cash received. The £0.7 million of cash held at the end of June should therefore be viewed separately from the headline profit when assessing the group's resources.
Sector and index Context
Listed venture and investment groups on AIM often trade at a discount to stated asset values, reflecting the difficulty of valuing unquoted holdings and the uncertain timing of exits. LSE:EMVC sits within the financial and investment segment of the FTSE AIM All Share Index, where sentiment toward early-stage healthcare and deep technology investment can shift with funding conditions.
Factors to Monitor
The largest gains in the interim period were non-cash, so the headline profit should be read alongside the underlying result and the cash position. Portfolio valuations depend on assumptions about businesses that are still developing, and realising value usually involves further funding rounds or sales. The cash balance of £0.7 million at the half-year is a figure to follow alongside the growth in revenue from core operations.
What to Watch Next
Market participants will look for the new advisory team to support fresh corporate activity, and for further progress at Glycotest, ProAxsis and AMR Bio. Any exits, fund raises or updates on assets under management will be important ahead of full-year results for 2026 from LSE:EMVC; results for 2025 were published in May this year.



_11_16_2026_12_57_23_264926.jpg)
_11_16_2026_12_39_02_969239.jpg)

Please wait processing your request...